Publications
Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, Coffin D, McCoy C, Schott A, Scholz C, Eckhardt SG. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, SNDX-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res, in press.
Gediya LK, Belosay
A, Khandelwal A, Purushottamachar P, Njar VC. Improved synthesis of histone
deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects
of HDIs alone or in combination with RAMBAs or retinoids on growth of human
LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem. 2007.
PM:18166465
» Abstract
Chen YD, Jiang
YJ, Zhou JW, Yu QS, You QD. Identification of ligand features essential
for HDACs inhibitors by pharmacophore modeling. J Mol Graph Model. 2007.
PM:18061500
» Abstract
Bayes M, Rabasseda
X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol.
2007;29(8):547-583. PM:18040531
» Abstract
Gao S, Mobley
A, Miller C, Boklan J, Chandra J. Potentiation of reactive oxygen species
is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in
leukemic cells. Leuk Res. 2007. PM:18031811
» Abstract
Chen CH, Lin
JY, Liu FH, Chang JL, Huang HM. Basic fibroblast growth factor inhibits
p38-mediated cell differentiation and growth inhibition by activin A but
not by histone deacetylase inhibitors in CML cells. Ann Hematol. 2008;87(3):175-182.
PM:17929017
» Abstract
Schroeder TM,
Nair AK, Staggs R, Lamblin AF, Westendorf JJ. Gene profile analysis of osteoblast
genes differentially regulated by histone deacetylase inhibitors. BMC Genomics.
2007;8:362. PM:17925016
» Abstract
Charrier C, Roche
J, Gesson JP, Bertrand P. Antiproliferative activities of a library of hybrids
between indanones and HDAC inhibitor SAHA and MS-275 analogues. Bioorg Med
Chem Lett. 2007;17(22):6142-6146. PM:17897824
» Abstract
Kummar S, Gutierrez
M, Gardner ER, et al. Phase I trial of MS-275, a histone deacetylase inhibitor,
administered weekly in refractory solid tumors and lymphoid malignancies.
Clin Cancer Res. 2007;13(18 Pt 1):5411-5417. PM:17875771
» Abstract
Ciossek T, Julius
H, Wieland H, Maier T, Beckers T. A homogeneous cellular histone deacetylase
assay suitable for compound profiling and robotic screening. Anal Biochem.
2008;372(1):72-81. PM:17868634
» Abstract
Khan N, Jeffers
M, Kumar S, et al. Determination of the class and isoform selectivity of
small-molecule histone deacetylase inhibitors. Biochem J. 2008;409(2):581-589.
PM:17868033
» Abstract
Kim BS, Bae E,
Kim YJ, et al. Combination of SK-7041, one of novel histone deacetylase
inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid
leukemia. Anticancer Drugs. 2007;18(6):641-647. PM:17762392
» Abstract
Baradari V, Hopfner
M, Huether A, Schuppan D, Scherubl H. Histone deacetylase inhibitor MS-275
alone or combined with bortezomib or sorafenib exhibits strong antiproliferative
action in human cholangiocarcinoma cells. World J Gastroenterol. 2007;13(33):4458-4466.
PM:17724801
» Abstract
Flotho C, Paulun
A, Batz C, Niemeyer CM. AKAP12, a gene with tumour suppressor properties,
is a target of promoter DNA methylation in childhood myeloid malignancies.
Br J Haematol. 2007;138(5):644-650. PM:17686059
» Abstract
Wang J, Mahmud
SA, Bitterman PB, Huo Y, Slungaard A. Histone deacetylase inhibitors suppress
TF-kappaB-dependent agonist-driven tissue factor expression in endothelial
cells and monocytes. J Biol Chem. 2007;282(39):28408-28418. PM:17675290
» Abstract
Kato Y, Yoshimura
K, Shin T, et al. Synergistic in vivo antitumor effect of the histone deacetylase
inhibitor MS-275 in combination with interleukin 2 in a murine model of
renal cell carcinoma. Clin Cancer Res. 2007;13(15 Pt 1):4538-4546. PM:17671140
» Abstract
Nishioka C, Ikezoe
T, Yang J, et al. Histone deacetylase inhibitors induce growth arrest and
apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear
factor kappaB. Leuk Res. 2007. PM:17644177
» Abstract
Nencioni A, Beck
J, Werth D, et al. Histone deacetylase inhibitors affect dendritic cell
differentiation and immunogenicity. Clin Cancer Res. 2007;13(13):3933-3941.
PM:17606727
» Abstract
Chen CS, Wang
YC, Yang HC, et al. Histone deacetylase inhibitors sensitize prostate cancer
cells to agents that produce DNA double-strand breaks by targeting Ku70
acetylation. Cancer Res. 2007;67(11):5318-5327. PM:17545612
» Abstract
Qian DZ, Wei
YF, Wang X, Kato Y, Cheng L, Pili R. Antitumor activity of the histone deacetylase
inhibitor MS-275 in prostate cancer models. Prostate. 2007;67(11):1182-1193.
PM:17520666
» Abstract
Di Renzo F, Broccia
ML, Giavini E, Menegola E. Relationship between embryonic histonic hyperacetylation
and axial skeletal defects in mouse exposed to the three HDAC inhibitors
apicidin, MS-275, and sodium butyrate. Toxicol Sci. 2007;98(2):582-588.
PM:17517827
» Abstract
Santini V, Gozzini
A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity
as a premise to clinical application. Curr Drug Metab. 2007;8(4):383-393.
PM:17504226
» Abstract
Tsapis M, Lieb
M, Manzo F, et al. HDAC inhibitors induce apoptosis in glucocorticoid-resistant
acute lymphatic leukemia cells despite a switch from the extrinsic to the
intrinsic death pathway. Int J Biochem Cell Biol. 2007;39(7-8):1500-1509.
PM:17499001
» Abstract
Sonnemann J,
Dreyer L, Hartwig M, et al. Histone deacetylase inhibitors induce cell death
and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma
cells. J Cancer Res Clin Oncol. 2007;133(11):847-858. PM:17486365
» Abstract
Beckers T, Burkhardt
C, Wieland H, et al. Distinct pharmacological properties of second generation
HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer.
2007;121(5):1138-1148. PM:17455259
» Abstract
Hess-Stumpp H,
Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor
of histone deacetylases--the development of an anticancer agent. Int J Biochem
Cell Biol. 2007;39(7-8):1388-1405. PM:17383217
» Abstract
Dong E, Guidotti
A, Grayson DR, Costa E. Histone hyperacetylation induces demethylation of
reelin and 67-kDa glutamic acid decarboxylase promoters. Proc Natl Acad
Sci U S A. 2007;104(11):4676-4681. PM:17360583
» Abstract
Miller CP, Ban
K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8
and ROS-dependent apoptosis alone and in combination with HDAC inhibitors
in leukemia cells. Blood. 2007;110(1):267-277. PM:17356134
» Abstract
Zhang M, Aguilera
D, Das C, et al. Measuring cytotoxicity: a new perspective on LC50. Anticancer
Res. 2007;27(1A):35-38. PM:17352213
» Abstract
Lin HS, Hu CY,
Chan HY, et al. Anti-rheumatic activities of histone deacetylase (HDAC)
inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol.
2007;150(7):862-872. PM:17325656
» Abstract
Picard V, Bergeron
A, Larue H, Fradet Y. MAGE-A9 mRNA and protein expression in bladder cancer.
Int J Cancer. 2007;120(10):2170-2177. PM:17290406
» Abstract
Furchert SE,
Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, Fruhwald MC. Inhibitors
of histone deacetylases as potential therapeutic tools for high-risk embryonal
tumors of the nervous system of childhood. Int J Cancer. 2007;120(8):1787-1794.
PM:17230517
» Abstract
Siebzehnrubl
FA, Buslei R, Eyupoglu IY, Seufert S, Hahnen E, Blumcke I. Histone deacetylase
inhibitors increase neuronal differentiation in adult forebrain precursor
cells. Exp Brain Res. 2007;176(4):672-678. PM:17216146
» Abstract
Kasman L, Lu
P, Voelkel-Johnson C. The histone deacetylase inhibitors depsipeptide and
MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without
adverse effects in normal prostate epithelial cells. Cancer Gene Ther. 2007;14(3):327-334.
PM:17186014
» Abstract
Gojo I, Jiemjit
A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone
deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood. 2007;109(7):2781-2790. PM:17179232
» Abstract
Baradari V, Huether
A, Hopfner M, Schuppan D, Scherubl H. Antiproliferative and proapoptotic
effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine
tumor cells. Endocr Relat Cancer. 2006;13(4):1237-1250. PM:17158768
» Abstract
Adcock IM. Histone
deacetylase inhibitors as novel anti-inflammatory agents. Curr Opin Investig
Drugs. 2006;7(11):966-973. PM:17117583
» Abstract
Lee KW, Kim JH,
Park JH, et al. Antitumor activity of SK-7041, a novel histone deacetylase
inhibitor, in human lung and breast cancer cells. Anticancer Res. 2006;26(5A):3429-3438.
PM:17094463
» Abstract
Vlasakova J,
Novakova Z, Rossmeislova L, Kahle M, Hozak P, Hodny Z. Histone deacetylase
inhibitors suppress IFNalpha-induced up-regulation of promyelocytic leukemia
protein. Blood. 2007;109(4):1373-1380. PM:17062732
» Abstract
Belien A, De
SS, Floren W, et al. Real-time gene expression analysis in human xenografts
for evaluation of histone deacetylase inhibitors. Mol Cancer Ther. 2006;5(9):2317-2323.
PM:16985066
» Abstract
Zhao M, Rudek
MA, Mnasakanyan A, Hartke C, Pili R, Baker SD. A liquid chromatography/tandem
mass spectrometry assay to quantitate MS-275 in human plasma. J Pharm Biomed
Anal. 2007;43(2):784-787. PM:16971082
» Abstract
Fouladi M. Histone
deacetylase inhibitors in cancer therapy. Cancer Invest. 2006;24(5):521-527.
PM:16939962
» Abstract
Cao H, Stamatoyannopoulos
G. Histone deacetylase inhibitor FK228 is a potent inducer of human fetal
hemoglobin. Am J Hematol. 2006;81(12):981-983. PM:16888791
» Abstract
Niedermeier A,
Talanin N, Chung EJ, et al. Histone deacetylase inhibitors induce apoptosis
with minimal viral reactivation in cells infected with Kaposi's sarcoma-associated
herpesvirus. J Invest Dermatol. 2006;126(11):2516-2524. PM:16810301
» Abstract
Hahnen E, Eyupoglu
IY, Brichta L, et al. In vitro and ex vivo evaluation of second-generation
histone deacetylase inhibitors for the treatment of spinal muscular atrophy.
J Neurochem. 2006;98(1):193-202. PM:16805808
» Abstract
Marcu MG, Jung
YJ, Lee S, et al. Curcumin is an inhibitor of p300 histone acetylatransferase.
Med Chem. 2006;2(2):169-174. PM:16787365
» Abstract
Holsken A, Eyupoglu
IY, Lueders M, et al. Ex vivo therapy of malignant melanomas transplanted
into organotypic brain slice cultures using inhibitors of histone deacetylases.
Acta Neuropathol. 2006;112(2):205-215. PM:16773328
» Abstract
Eyupoglu IY,
Hahnen E, Trankle C, et al. Experimental therapy of malignant gliomas using
the inhibitor of histone deacetylase MS-275. Mol Cancer Ther. 2006;5(5):1248-1255.
PM:16731757
» Abstract
Moody TW, Nakagawa
T, Kang Y, Jakowlew S, Chan D, Jensen RT. Bombesin/gastrin-releasing peptide
receptor antagonists increase the ability of histone deacetylase inhibitors
to reduce lung cancer proliferation. J Mol Neurosci. 2006;28(3):231-238.
PM:16691010
» Abstract
Takai N, Ueda
T, Nishida M, Nasu K, Narahara H. Anticancer activity of MS-275, a novel
histone deacetylase inhibitor, against human endometrial cancer cells. Anticancer
Res. 2006;26(2A):939-945. PM:16619490
» Abstract
Sato T, Suzuki
M, Sato Y, Echigo S, Rikiishi H. Sequence-dependent interaction between
cisplatin and histone deacetylase inhibitors in human oral squamous cell
carcinoma cells. Int J Oncol. 2006;28(5):1233-1241. PM:16596240
» Abstract
Nagaoka Y, Maeda
T, Kawai Y, et al. Synthesis and cancer antiproliferative activity of new
histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing
derivatives. Eur J Med Chem. 2006;41(6):697-708. PM:16584813
» Abstract
Acharya MR, Karp
JE, Sausville EA, et al. Factors affecting the pharmacokinetic profile of
MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Invest New Drugs. 2006;24(5):367-375. PM:16583304
» Abstract
Blum W, Marcucci
G. Targeting epigenetic changes in acute myeloid leukemia. Clin Adv Hematol
Oncol. 2005;3(11):855-65, 882. PM:16491631
» Abstract
Simonini MV,
Camargo LM, Dong E, et al. The benzamide MS-275 is a potent, long-lasting
brain region-selective inhibitor of histone deacetylases. Proc Natl Acad
Sci U S A. 2006;103(5):1587-1592. PM:16432198
» Abstract
Witta SE, Gemmill
RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity
to epidermal growth factor receptor inhibitors in lung cancer cell lines.
Cancer Res. 2006;66(2):944-950. PM:16424029
» Abstract
Kouraklis G,
Theocharis S. Histone deacetylase inhibitors: a novel target of anticancer
therapy (review). Oncol Rep. 2006;15(2):489-494. PM:16391874
» Abstract
Schroeder TM,
Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation.
J Bone Miner Res. 2005;20(12):2254-2263. PM:16294278
» Abstract
Shankar S, Singh
TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK. Interactive effects of
histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia
cells: involvement of both death receptor and mitochondrial pathways. Int
J Mol Med. 2005;16(6):1125-1138. PM:16273296
» Abstract
Chung EJ, Lee
S, Sausville EA, et al. Histone deacetylase inhibitor pharmacodynamic analysis
by multiparameter flow cytometry. Ann Clin Lab Sci. 2005;35(4):397-406.
PM:16254255
» Abstract
Early clinical
data and potential clinical utility of novel histone deacetylase inhibitors
in prostate cancer. Clin Prostate Cancer. 2005;4(2):83-85. PM:16197607
» Abstract
Liu AL, Long
J, Wang N, Du GH. [A new target of cancer therapy: advances in the study
of histone deacetylase]. Yao Xue Xue Bao. 2005;40(7):585-590. PM:16196262
» Abstract
Varghese S, Gupta
D, Baran T, et al. Alkyl-substituted polyaminohydroxamic acids: a novel
class of targeted histone deacetylase inhibitors. J Med Chem. 2005;48(20):6350-6365.
PM:16190761
» Abstract
Chen CS, Weng
SC, Tseng PH, Lin HP, Chen CS. Histone acetylation-independent effect of
histone deacetylase inhibitors on Akt through the reshuffling of protein
phosphatase 1 complexes. J Biol Chem. 2005;280(46):38879-38887. PM:16186112
» Abstract
VanOosten RL,
Moore JM, Karacay B, Griffith TS. Histone deacetylase inhibitors modulate
renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing
TRAIL-R2 expression. Cancer Biol Ther. 2005;4(10):1104-1112. PM:16096370
» Abstract
Acharya MR, Sparreboom
A, Sausville EA, et al. Interspecies differences in plasma protein binding
of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol.
2006;57(3):275-281. PM:16028097
» Abstract
Ryu JK, Lee WJ,
Lee KH, et al. SK-7041, a new histone deacetylase inhibitor, induces G2-M
cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer
Lett. 2006;237(1):143-154. PM:16009488
» Abstract
Dai Y, Rahmani
M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65
acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells
through a process mediated by oxidative damage, XIAP downregulation, and
c-Jun N-terminal kinase 1 activation. Mol Cell Biol. 2005;25(13):5429-5444.
PM:15964800
» Abstract
Singh TR, Shankar
S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential
of TRAIL in breast carcinoma. Oncogene. 2005;24(29):4609-4623. PM:15897906
» Abstract
Wang XF, Qian
DZ, Ren M, et al. Epigenetic modulation of retinoic acid receptor beta2
by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Clin Cancer Res. 2005;11(9):3535-3542. PM:15867257
» Abstract
Ryan QC, Headlee
D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone
deacetylase inhibitor, in patients with advanced and refractory solid tumors
or lymphoma. J Clin Oncol. 2005;23(17):3912-3922. PM:15851766
» Abstract
Wang Y, Curry
HM, Zwilling BS, Lafuse WP. Mycobacteria inhibition of IFN-gamma induced
HLA-DR gene expression by up-regulating histone deacetylation at the promoter
region in human THP-1 monocytic cells. J Immunol. 2005;174(9):5687-5694.
PM:15843570
» Abstract
Hess-Stumpp H.
Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
Eur J Cell Biol. 2005;84(2-3):109-121. PM:15819394
» Abstract
Pruss A, Kempter
C, Gysler J, Maier-Rosenkranz J, Jira T. Peak shape improvement of basic
analytes in capillary liquid chromatography. J Sep Sci. 2005;28(3):291-294.
PM:15776933
» Abstract
Qian DZ, Ren
M, Wei Y, et al. In vivo imaging of retinoic acid receptor beta2 transcriptional
activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant
prostate cancer cells. Prostate. 2005;64(1):20-28. PM:15651062
» Abstract
Monneret C. Histone
deacetylase inhibitors. Eur J Med Chem. 2005;40(1):1-13. PM:15642405
» Abstract
Ungerstedt JS,
Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and
transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci
U S A. 2005;102(3):673-678. PM:15637150
» Abstract
Glaser KB, Li
J, Pease LJ, et al. Differential protein acetylation induced by novel histone
deacetylase inhibitors. Biochem Biophys Res Commun. 2004;325(3):683-690.
PM:15541343
» Abstract
Camphausen K,
Scott T, Sproull M, Tofilon PJ. Enhancement of xenograft tumor radiosensitivity
by the histone deacetylase inhibitor MS-275 and correlation with histone
hyperacetylation. Clin Cancer Res. 2004;10(18 Pt 1):6066-6071. PM:15447991
» Abstract
Park JH, Jung
Y, Kim TY, et al. Class I histone deacetylase-selective novel synthetic
inhibitors potently inhibit human tumor proliferation. Clin Cancer Res.
2004;10(15):5271-5281. PM:15297431
» Abstract
Piekarz R, Bates
S. A review of depsipeptide and other histone deacetylase inhibitors in
clinical trials. Curr Pharm Des. 2004;10(19):2289-2298. PM:15279609
» Abstract
Acharya MR, Figg
WD. Histone deacetylase inhibitor enhances the anti-leukemic activity of
an established nucleoside analogue. Cancer Biol Ther. 2004;3(8):719-720.
PM:15254393
» Abstract
Marks PA, Richon
VM, Kelly WK, Chiao JH, Miller T. Histone deacetylase inhibitors: development
as cancer therapy. Novartis Found Symp. 2004;259:269-281. PM:15171260
» Abstract
Lucas DM, Davis
ME, Parthun MR, et al. The histone deacetylase inhibitor MS-275 induces
caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.
Leukemia. 2004;18(7):1207-1214. PM:15116122
» Abstract
Hwang K, Acharya
MR, Sausville EA, et al. Determination of MS-275, a novel histone deacetylase
inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804(2):289-294. PM:15081922
» Abstract
Zhang Y, Adachi
M, Zhao X, Kawamura R, Imai K. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino-
methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced
cell death in gastrointestinal adenocarcinoma cells. Int J Cancer. 2004;110(2):301-308.
PM:15069698
» Abstract
Maggio SC, Rosato
RR, Kramer LB, et al. The histone deacetylase inhibitor MS-275 interacts
synergistically with fludarabine to induce apoptosis in human leukemia cells.
Cancer Res. 2004;64(7):2590-2600. PM:15059916
» Abstract
Li J, Staver
MJ, Curtin ML, et al. Expression and functional characterization of recombinant
human HDAC1 and HDAC3. Life Sci. 2004;74(22):2693-2705. PM:15043985
» Abstract
Camphausen K,
Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation
of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.
Cancer Res. 2004;64(1):316-321. PM:14729640
» Abstract
Bouchain G, Delorme
D. Novel hydroxamate and anilide derivatives as potent histone deacetylase
inhibitors: synthesis and antiproliferative evaluation. Curr Med Chem. 2003;10(22):2359-2372.
PM:14529479
» Abstract
Rahmani M, Yu
C, Reese E, et al. Inhibition of PI-3 kinase sensitizes human leukemic cells
to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase
inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT
inhibition. Oncogene. 2003;22(40):6231-6242. PM:13679862
» Abstract
Hu E, Dul E,
Sung CM, et al. Identification of novel isoform-selective inhibitors within
class I histone deacetylases. J Pharmacol Exp Ther. 2003;307(2):720-728.
PM:12975486
» Abstract
Rosato RR, Almenara
JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation
or apoptosis in human leukemia cells through a process regulated by generation
of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res.
2003;63(13):3637-3645. PM:12839953
» Abstract
Kouraklis G,
Theocharis S. Histone deacetylase inhibitors and anticancer therapy. Curr
Med Chem Anticancer Agents. 2002;2(4):477-484. PM:12678732
» Abstract
Glaser KB, Staver
MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling
of multiple histone deacetylase (HDAC) inhibitors: defining a common gene
set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol
Cancer Ther. 2003;2(2):151-163. PM:12589032
» Abstract
Jaboin J, Wild
J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has
marked in vitro and in vivo antitumor activity against pediatric solid tumors.
Cancer Res. 2002;62(21):6108-6115. PM:12414635
» Abstract
Rossig L, Li
H, Fisslthaler B, et al. Inhibitors of histone deacetylation downregulate
the expression of endothelial nitric oxide synthase and compromise endothelial
cell function in vasorelaxation and angiogenesis. Circ Res. 2002;91(9):837-844.
PM:12411399
» Abstract
Witt O, Monkemeyer
S, Ronndahl G, et al. Induction of fetal hemoglobin expression by the histone
deacetylase inhibitor apicidin. Blood. 2003;101(5):2001-2007. PM:12393499
» Abstract
Fournel M, Trachy-Bourget
MC, Yan PT, et al. Sulfonamide anilides, a novel class of histone deacetylase
inhibitors, are antiproliferative against human tumors. Cancer Res. 2002;62(15):4325-4330.
PM:12154036
» Abstract
Park SH, Lee
SR, Kim BC, et al. Transcriptional regulation of the transforming growth
factor beta type II receptor gene by histone acetyltransferase and deacetylase
is mediated by NF-Y in human breast cancer cells. J Biol Chem. 2002;277(7):5168-5174.
PM:11744689
» Abstract
Yoshida M, Furumai
R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase
as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001;48
Suppl 1:S20-S26. PM:11587361
» Abstract
Jung M. Inhibitors
of histone deacetylase as new anticancer agents. Curr Med Chem. 2001;8(12):1505-1511.
PM:11562279
» Abstract
Lee BI, Park
SH, Kim JW, et al. MS-275, a histone deacetylase inhibitor, selectively
induces transforming growth factor beta type II receptor expression in human
breast cancer cells. Cancer Res. 2001;61(3):931-934. PM:11221885
» Abstract
Suzuki T, Ando
T, Tsuchiya K, et al. Synthesis and histone deacetylase inhibitory activity
of new benzamide derivatives. J Med Chem. 1999;42(15):3001-3003. PM:10425110
» Abstract
Saito A, Yamashita
T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275,
with marked in vivo antitumor activity against human tumors. Proc Natl Acad
Sci U S A. 1999;96(8):4592-4597. PM:10200307
» Abstract
